⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CORT News
Corcept Therapeutics Inc.
Primärer Endpunkt der Gesamtüberlebensrate in der zulassungsrelevanten Phase-3-Studie ROSELLA von Corcept mit Relacorilant bei Patientinnen mit platinresistentem Eierstockkrebs erreicht
businesswire.com
CORT
El crucial ensayo ROSELLA fase 3 de relacorilant de Corcept cumplió el criterio de evaluación principal de supervivencia general en pacientes con cáncer ovárico resistente al platino
businesswire.com
CORT
Critère principal de survie globale atteint dans l’essai pivot ROSELLA de phase 3 de Corcept évaluant le rélacorilant chez les patientes atteintes d’un cancer de l’ovaire résistant au platine
businesswire.com
CORT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
prnewswire.com
CORT
Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
businesswire.com
CORT
CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm
prnewswire.com
CORT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
accessnewswire.com
CORT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
globenewswire.com
CORT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
globenewswire.com
CORT
Bronstein, Gewirtz & Grossman, LLC Is Investigating Corcept Therapeutics Incorporated (CORT) And Encourages Shareholders to Connect
accessnewswire.com
CORT